Keywords: AstraZeneca, Third-quarter 2010 financial results, Law suit, Watson, Crestor
AstraZeneca sees 3rd-qtr 2010 earnings slump 27%, hit by charges and generic competition; sues Watson
Article | 28 October 2010
Generic competition, as well as restructuring and legal costs have taken a hefty toll on AstraZeneca’s (LSE: AZN) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
